Erik Tillman

Erik Tillman

Company: Akero Therapeutics

Job title: Principal Scientist


What the Latest Advances in Our Understanding of NASH Pathogenesis & Pathophysiology Can Tell Us About Past & Future Therapeutic Approaches 1:30 pm

• Outlining our understanding of the pathogenesis and pathophysiology of NAFLD and NASH, from the molecular to the whole-body level • Hearing what clinical trials in NASH have taught us about different therapeutic targets and pathways, and why “what you measure” matters • Integrating the latest basic, translational, and clinical research to improve NASH therapeutic…Read more

day: Day 2 Stream 1 PM

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.